North Carolina Patent of the Month – October 2023

410 Medical, Inc. is on a mission to help save lives. Their approach is to develop the innovative tools and technologies that assist healthcare providers in improving resuscitation. In this effort, the company has been granted a patent for their fluid infusion technology. Their system, a seamless fusion of a fluid delivery assembly and a drive assembly, has the potential to revolutionize the way intravenous fluids and blood products are administered.

Traditional rapid infusers have their limitations. They can be unwieldy and challenging to set up. Their capacity to generate pressure is capped, which restricts the flow rates through peripheral IVs. Furthermore, they produce a pulsatile pressure profile, leading to suboptimal flow rates and increased peak pressures. These constraints present challenges, especially when quick and efficient fluid delivery is critical, as is often the case in emergency medical situations.

410 Medical’s system, marketed as LifeFlow, aims to simplify transportation, setup, and user control while ensuring a continuous, non-pulsatile flow of fluids, even through peripheral IV sites. The handheld system provides a portable infuser solution capable of rapidly delivering blood or other resuscitative fluids. This means, when in the field, patients with life-threatening bleeding can begin receiving treatment right away.

This is achieved using a fluid channel which contains a blood filter, an air check, and a force reducer. Each component plays a crucial role in ensuring the fluid is delivered to the patient with care. The rate of delivery can be controlled by the operator, adjusting speed in response to the patient’s needs. On an engineering level, this is achieved with a fluid delivery assembly coupled to a drive assembly. This coupling provides a continuous and non-pulsatile fluid flow.

410 Medical’s approach to treatment is faster than traditional systems. With a set up time of less than 2 minutes and an ability to deliver 500 mL of blood in under 2 minutes, patients can be stabilized and moved into the next stage of treatment sooner than ever.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts